Sector: Pharmaceuticals Biotechnology and Life Sciences

Investors are riding a wave of unprecedented optimism following what seems like an avalanche of biotech deals, early drug approvals, and positive clinical news that has kicked off the year. TheStreet.com reports.   Read More

It’s rare for the world's leading pharmaceutical companies and other partners to work together to tackle an urgent global health issue. It’s time for this to change and our new coordinated effort – unlike previous siloed, disease-by-disease approaches – is the first step.   Read More

Amgen and Celgene, looking to boost oncology offerings, announced separate deals for small biotech companies Thursday, the latest in what analysts expect to be a major wave of biotech mergers.    Read More

Alkermes expects FDA approval for its new diabetes drug this month, but that might not be enough to make the stock worth buying, trader Guy Adami said.    Read More

Is legislated healthcare reform here to stay? As we watch the presidential race heat up – and look to a Supreme Court ruling this summer — no one knows for sure. Regardless, we as a nation need to realize that traditional thinking around healthcare is forever changed.    Read More

In the next 14 months, patents for the top 20 drugs in the U.S. are set to expire. Although makers of such top-selling drugs, such as Lipitor and Plavix, will no longer have a monopoly on these drug formulas, pharmaceutical stocks will be able to weather the loss of these patents, said two health-care analysts.   Read More